Alterity Therapeutics Ltd
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.
The business
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA
Alterity Therapeutics (ASX: ATH) has released positive topline data from an open label Phase 2 clinical trial of lead candidate ATH434 on 10 patients with advanced multiple system atrophy (MSA). Data from the ATH434-202 trial showed the oral drug conferred a clinical benefit on areas of impairment in MSA and was able to stabilise key […]
Alterity Therapeutics shows positive ATH434 Phase 2 trial results for Multiple System Atrophy
Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ATH434-201 on patients with early-stage multiple system atrophy (MSA). ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. MSA is a rare neurodegenerative disease characterised by failure of the autonomic […]
Alterity Therapeutics’ ATH434 trial results suggest improved outcomes for MSA Patients
Alterity Therapeutics (ASX: ATH) has released positive interim data from an open-label Phase 2 clinical trial of its lead asset ATH434, showing stable or improved neurological symptoms in patients with multiple system atrophy (MSA). The analysis of a total of ten participants included clinical and biomarker data on seven who were treated with daily oral […]
Alterity Therapeutics receives funding from Michael J Fox Foundation for Parkinson’s disease clinical trials
Biotech company Alterity Therapeutics (ASX: ATH) has received funding from the Michael J Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 in Parkinson’s disease clinical trials. This funding for US$495,000 (A$641,500) is the second grant the company has received from the foundation and will be used to evaluate […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.